Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcareFRA:PBV +2.82%72 Quick Ratio is 1.99 as of Jun. 2026, which is 38% above its 10-year median of 1.44. GuruFocus rates FRA:PBV with a GF Score™ of 72/100 and a GF Value™ of €59.76 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 994 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 63.88% on this metric.
Prestige Consumer Healthcare (FRA:PBV) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Prestige Consumer Healthcare Quick Ratio Related Terms
Prestige Consumer Healthcare Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PBV vs BCRX, AMLX, SUPN: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's Quick Ratio falls into.
Prestige Consumer Healthcare Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prestige Consumer Healthcare (FRA:PBV) has a Quick Ratio of 1.99 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Prestige Consumer Healthcare and its competitors. This is 38% above median its historical median of 1.44. Over the past decade, Prestige Consumer Healthcare's Quick Ratio has ranged from 1.14 to 2.99. According to the industry distribution chart, Prestige Consumer Healthcare ranks #359 out of 994 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is Prestige Consumer Healthcare's Quick Ratio too high?
Prestige Consumer Healthcare's current Quick Ratio of 1.99 is 38% above median its 10-year median of 1.44. Over the past 10 years, this metric has ranged from a low of 1.14 to a high of 2.99. The Drug Manufacturers industry median Quick Ratio is 1.43. Prestige Consumer Healthcare's value of 1.99 is 39.2% above this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #359 out of 994 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Prestige Consumer Healthcare has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Quick Ratio compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #359 out of 994 companies for Quick Ratio. This puts Prestige Consumer Healthcare in the upper half of its industry. The industry median Quick Ratio is 1.43. Prestige Consumer Healthcare's value of 1.99 is 39.2% above this benchmark. Historically, Prestige Consumer Healthcare's own Quick Ratio has ranged from 1.14 to 2.99 over the past decade. While the company's 10-year median is 1.44 vs. the industry median of 1.43, Prestige Consumer Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.43, based on 994 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current Quick Ratio of 1.99 is 39.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current Quick Ratio is 1.99, which is 38% above median its own 10-year median of 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (FRA:PBV) is currently considered Modestly Undervalued. The stock's GF Value™ is €59.76, compared to a current price of €43.80 — trading 26.7% below its estimated fair value. The current Quick Ratio is 1.99, which is 38% above median its 10-year median of 1.44 and 39.2% above the Drug Manufacturers industry median of 1.43. Prestige Consumer Healthcare's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Prestige Consumer Healthcare (FRA:PBV), the current Quick Ratio is 1.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (FRA:PBV) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of €43.80 is trading 26.7% below its estimated GF Value™ of €59.76.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for FRA:PBV:
Quick Ratio: 1.99 (38% above median its 10-year median of 1.44)
GF Value™: €59.76 vs. price of €43.80 (26.7% below fair value)
Industry Position: 39.2% above the Drug Manufacturers median (#359 of 994)
No single metric tells the full story. See the FRA:PBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
72GF Score
Get the complete analysis for FRA:PBV
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBV has been successfully added to your 
